TORONTO, Sept. 4, 2012 /CNW/ - Patheon Inc. (TSX: PTI), a leading
provider of contract development and manufacturing services to the
global pharmaceutical industry, announced today that it will report its
third quarter fiscal 2012 financial results on Thursday, September 13,
In conjunction with its financial results announcement, Patheon will
host a conference call Thursday, September 13, 2012 at 8:30 a.m.
(EDT). The financial results news release will be issued at
approximately 7:00 a.m. (EDT) Thursday, September 13, 2012.
Interested parties are invited to access the conference call, via
telephone, in listen-only mode, toll free at 1-888-231-8191 (U.S.,
including Puerto Rico) and 1-647-427-7450 (Canada and International).
Listeners are encouraged to dial in five to fifteen minutes in advance
to avoid delays. Slides will also be available for viewing during the
call by accessing http://ir.patheon.com/events.cfm
A telephone replay of the conference call will be available between
Thursday, September 13, 2012 and Thursday, September 27, 2012 by
dialling 1-855-859-2056 (toll free) or 1-403-451-9481, and by entering identification number
19083494, followed by the number key. The conference call will be
archived at http://ir.patheon.com/events.cfm.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, solid and liquid forms. Patheon uses many
innovative technologies including single-use disposables, soft gel,
liquid-filled hard capsules and a variety of modified release
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
Patheon can take customers direct to clinic with global clinical
packaging and distribution services and Patheon's Quick to Clinic™
programs can accelerate early phase development projects to clinical
trials while minimizing the consumption of valuable API. The company's
integrated development and manufacturing network of 10 manufacturing
facilities, eight development centers and one clinical trial material
packaging facility across North America and Europe, enables customer
products to be launched with confidence anywhere in the world.
SOURCE: Patheon Inc.
For further information:
Investor Relations and Corporate Communications